CTOs on the Move


 
InnovoTex Inc. is a mid-stage pharmaceutical company developing the TEX Core portfolio of novel therapeutics capable of targeting multiple solid tumor indications.
  • Number of Employees: 0-25
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Similar Companies

Rhoads Pharmacy

Rhoads Pharmacy is a Hummelstown, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Angstrom Pharmaceuticals

Angstrom Pharmaceuticals is a Solana Beach, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Jennerex Biotherapeutics

Jennerex Biotherapeutics is a San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

MyDental360

MyDental360 - Know what matters. Find what works. Powered by Kulzer The information you want on the subjects that affect your everyday work. We cover them from every angle—in a concise view delivered right to your inbox. Your Benefits • Busine...

Akcea Therapeutics

Akcea Therapeutics is a development and commercialization company focused on helping patients with serious diseases. Our priority is to drive clinical program execution, understand patient and physician needs, prepare the market, create market access, and commercialize our products on a global basis. We are driven by knowing that patients depend on us. An affiliate of Ionis Pharmaceuticals and based in Kendall Square, Cambridge, Massachusetts, Akcea was founded with a robust portfolio of development-stage drugs covering multiple targets and disease states using advanced antisense therapeutics. Akcea is derived from the Greek word for value and worth. Something that has akcea (αξία) is not common, but precious and rare. Our name supports the value we are creating for physicians, patients and their families, and other key stakeholders as we seek to commercialize a robust portfolio of development-stage, advanced, antisense therapies for serious cardiometabolic lipid disorders. Our immediate focus is to drive our clinical programs forward through development to commercialization while building on the Isis standards of excellence.